ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Visolyr and HITLAB Partner to Advance AI Solutions for Women’s Health and Cardiometabolic Disease

(PRUnderground) May 27th, 2025

Visolyr, a digital health platform focused on AI-powered clinical solutions, has partnered with HITLAB, a leading health innovation research lab, to accelerate the development and validation of a breakthrough Generative AI platform designed to transform healthcare delivery.

Under a strategic services agreement, HITLAB will support Visolyr in building and refining its Generative and Agentic AI platform for healthcare through rigorous validation research, publication, business model development, investor engagement, and strategic partnerships. The collaboration aims to bring to market a clinically validated solution that improves clinical documentation, enhances decision support, elevates patient engagement and education, and strengthens medication management.

Visolyr’s AI platform is engineered to accelerate digital health transformation by integrating Generative AI, AI agents, and intelligent automation directly into clinical workflows. With a focus on women’s health and high-burden conditions such as cardiometabolic diabetes—particularly in patients with kidney disease and hypertension—Visolyr delivers personalized, proactive, and coordinated care. The platform enables enterprise-wide AI deployments that enhance clinician efficiency and improve patient experiences at the point of care.

Through its participation in the NVIDIA Inception program, Visolyr has deployed NVIDIA Inference Microservices (NIM) to deliver sub-second, context-aware AI responses. This has powered Visolyr’s latest demo capabilities, which include hybrid AI workflows, Retrieval-Augmented Generation (RAG) automation, and optimized routing.

“HITLAB is committed to accelerating the adoption of impactful technologies that address unmet healthcare needs,” said Dr. Stan Kachnowski, Chair of HITLAB. “Our collaboration with Visolyr reflects our shared vision of using cutting-edge AI to streamline clinical processes, improve outcomes, and reduce costs.”

Visolyr Founder and CEO Michael Joseph added, “Our partnership with HITLAB is a critical milestone in our mission to bring context-aware AI to the point of care. Together, we are advancing a platform that not only empowers clinicians but also personalizes the care journey for patients.”

HITLAB, known for initiatives such as the HITLAB World Cup, Women’s Health Tech Initiative, and Breakthrough Alliance, will also help position Visolyr’s innovation within the broader healthcare ecosystem through seminars, conferences, and thought leadership.

About Visolyr
Visolyr is a healthcare AI platform that enables enterprise-scale deployment of Generative AI and intelligent agents within clinical workflows. Focused on enhancing clinical decision-making and streamlining care for complex chronic conditions, Visolyr is on a mission to improve health outcomes, provider productivity and operational efficiency through next-generation technology at the forefront of AI innovation.

About HITLAB

HITLAB is an impact-first organization that offers digital health research, teaching, and advisory services to improve health delivery around the world.

At HITLAB, we believe technology and health can work together to improve the quality of health delivery and healthcare worldwide. We use rigorous research and evidence-based methods to identify the best digital health solutions for each of our partners.

The post Visolyr and HITLAB Partner to Advance AI Solutions for Women’s Health and Cardiometabolic Disease first appeared on

Press Contact

Name: Rachel Fredman
Phone: 516-310-1583
Email: Contact Us

Original Press Release.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.